According to a January 2024 press release from Accord BioPharma, Inc. ("Accord"), the FDA accepted Accord's abbreviated Biologics License Application (aBLA) for DMB-3115 (ustekinumab), a proposed biosimilar to Janssen Biotech's (a Johnson & Johnson company) Stelara® (ustekinumab). According to Accord's press release, Accord also publicly disclosed for the first time that it previously submitted aBLAs for a filgrastim (Neupogen®) biosimilar and a pegfilgrastim (Neulasta®) biosimilar.
In 2013, Dong-A Socio Holdings and Meiji Seika Pharma began joint development for DMB-3115, with exclusive rights granted to Intas Pharmaceuticals after a partnership was announced in 2021. Accord, a subsidiary of Intas Pharmaceuticals, will be responsible for commercialization of DMB-3115 in the United States.
This is the fifth pending aBLA for a proposed biosimilar of Stelara®. According to Accord's press release, it reached a settlement with Janssen in October 2023, prior to any biosimilar patent disputes in the United States, that would allow it to launch DMB-3115 in the United States no later than May 15, 2025, pending its approval by the FDA.
J&J reported that Stelara® had U.S. sales of about $6.97B in 2023. We continue to monitor this aBLA. For more information on pending aBLAs and biosimilar-related patent disputes, please visit BiologicsHQ.com.
The authors would like to thank April Breyer Menon for her contributions to this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.